Core Viewpoint - The legal opinion letter indicates that Shenzhen Tongzhou Electronics Co., Ltd. has resolved the conditions that led to the implementation of delisting risk warnings and other risk warnings, allowing the company to apply for the removal of these warnings from its stock trading status [3][10][17]. Group 1: Company Financial Performance - The audited net profit for the year 2023 was negative, and the operating revenue was below 100 million yuan, triggering delisting risk warnings [3][5]. - For the year 2024, the company reported a net profit of 69,609,438.04 yuan and an operating revenue of 599,444,121.84 yuan, indicating a significant recovery [6][15]. - The company’s net assets as of December 31, 2024, were reported at 87,079,501.17 yuan, showing improvement in financial stability [6][7]. Group 2: Risk Warnings and Resolutions - The company faced delisting risk warnings due to negative net profits over three consecutive years and uncertainty in its ability to continue operations [3][10]. - The company has resolved the issues leading to the delisting risk warnings and has submitted an application to the Shenzhen Stock Exchange for their removal [10][11]. - Other risk warnings were also addressed, with the company confirming that frozen funds amounted to only 710,100.23 yuan, which is negligible compared to its total net assets [6][11]. Group 3: Compliance with Regulations - The company has complied with the Shenzhen Stock Exchange's regulations, demonstrating that it does not meet any of the conditions for continued delisting risk warnings [10][17]. - The legal opinion confirms that the company has maintained effective internal controls and has not faced any significant financial reporting issues [9][13]. - The company has fulfilled its disclosure obligations and has not received any administrative penalties related to its financial reporting [16][17].

Group 1 - The company will participate in the "2024 Annual Performance Briefing and Investor Reception Day" on May 13, 2025, to enhance communication with investors regarding its annual report and other key topics [1] - The company has received marketing authorization from the Therapeutic Goods Administration (TGA) in Australia for its injectable drug Bivalirudin, which is indicated as an anticoagulant for high-risk acute coronary syndrome patients [3][4] - The injectable Bivalirudin has previously received approvals from various regulatory bodies, including the FDA in the United States and the Saudi Arabian SFDA [5] Group 2 - The company's stock has experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 12% over two consecutive trading days [9] - The company has confirmed that there are no undisclosed significant matters that could affect its stock price, and it has conducted a thorough review of its recent trading activity [10][11] - The company has been placed under a delisting risk warning due to negative financial results, with the lowest of its audited profit total, net profit, and net profit after non-recurring gains and losses being negative, and revenue below 300 million [12]

Financial Performance - In Q1 2025, the company reported revenue of 0.80 billion yuan, a decrease of 72.59% year-on-year [1][2] - The net profit attributable to shareholders was -0.56 billion yuan, compared to -1.04 billion yuan in the same period last year [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -0.60 billion yuan, unchanged from the previous year [1][2] - The net cash flow from operating activities was -1.18 billion yuan, slightly worse than -1.12 billion yuan in the same period last year [1][4] Annual Report Insights - For the year 2024, the company achieved revenue of 9.49 billion yuan, a slight decline of 0.60% year-on-year [4][5] - The net profit attributable to shareholders for 2024 was -7.27 billion yuan, compared to -2.48 billion yuan in 2023 [4][5] - The net cash flow from operating activities for 2024 was -5.06 billion yuan, a significant drop from 1.48 billion yuan in 2023 [4][6] Audit and Compliance Issues - The company received a negative audit opinion from Tianjian Accounting Firm regarding its 2024 financial report, leading to a risk warning for its stock [7][8] - The company acknowledged management issues, resulting in overpayments to suppliers totaling 180 million yuan, with the chairman committing to recover these funds [7] - The stock will be suspended from trading starting April 30, 2025, and will resume trading with a risk warning on May 6, 2025 [8] Stock Market Performance - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 19, 2022, with an initial public offering price of 51.88 yuan per share [8] - The stock reached a peak price of 45.92 yuan on its first trading day but has since been in a downward trend, currently trading below its IPO price [8] - The total funds raised from the IPO amounted to approximately 1.74 billion yuan, exceeding the planned amount by 85.75 million yuan [8][9]

Core Viewpoint - The company *ST Weidi (603023)* has eliminated the conditions that triggered the delisting risk warning and has applied to the Shanghai Stock Exchange for the withdrawal of this warning [1] Group 1 - The company has submitted an application to the Shanghai Stock Exchange to revoke the delisting risk warning [1] - The final outcome of the application will depend on the review by the Shanghai Stock Exchange [1] - The company's stock will continue to trade normally during the review period [1]